Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: JanyBlueEyes who wrote (4405)	8/13/1998 1:43:00 PM
From: Mama Bear	Read Replies (1) \| Respond to of 5736

"I was told the lines were 8 deep with people to view the TLc-Bilitest. Spectrx's booth sat lonely and isolated. " Then it's even stranger that CCSI has generated no revenue, while SPRX has generated revenues. You just don't get it Janybird, it's all about selling the product. CCSI has had FDA approval for over a year, but not a penny of revenue. They are certainly good at generating fluff press releases blowing their own horn. In the meantime, SPRX quietly goes about actually selling their product, and generating revenues even though they haven't received FDA approval. A company's success is measured by the amount of money it takes in, not the number of press releases it puts out or the number of posts to it's Internet opinion thread. Barb

To: JanyBlueEyes who wrote (4405)	8/13/1998 2:49:00 PM
From: Robin	Read Replies (2) \| Respond to of 5736

Jany, Obviously CCSI did a better job than SPRX at publicizing their product before the convention and my hat is off to them! I wish I could say the same for SPRX. But you do have to keep in mind that the bilirubin product will not be the majority revenue producer for SPRX 2-3 years from now if all goes to plan, hence their less than enthusiastic (fanatic) promotion of the product. The end result, as you rightly pointed out, was the large interest at the CCSI booth relative to the SPRX booth. 'Sheep come where they are called'. Keep in mind, the focus at SPRX is the successful completion of the diabetes product. The ultimate value to SPRX in the bilirubin product is to provide experience in the areas of clinical trials, FDA submittal, marketing, manufacturing, and distribution in preparation for the diabetes product. SPRX does not need a successful launch of the bilirubin product to survive, but CCSI does! This is a BIG difference. As for QUALITY, I do not see any study publicly available that has compared the performance / accuracy of the Bilichek vs. the Colormate, so anyone at this point making claims as to one product being superior over the other is likely to be blowing a lot of wind. I for one would not dare claim quality or technical excellence of the SPRX device over the CCSI device or vice versa based on the information I have seen to date. Do you dare? On what basis or what factual information is there that you can disclose which would validate your claim and make your statement credible? I would like to see this information if you have some and give it fair consideration. Also, keep in mind that technical excellence of one product over another does not guarantee its success. Look at the example of VHS vs. BETA for a lesson there. It all boils down on how good at one is in getting into the marketplace and making those sales! You need to remember that the money to be made in the bilirubin market is going to be made on disposables; the instrument will be sold at or below cost. This mandates that the company that makes the most sales first has the highest likelihood of success. SPRX is shipping, CCSI is not! Nuf said! Rockin' Robin